DOI · e01.org

Optimizing Clinical Trial Design through In Silico Modeling, Virtual Populations, and Mathematical Optimization

Evgueni Jacob, Riad Kahoul, Eliott Tixier · container not stated · 2026

  • DOI 10.70534/zdzu1663
  • Publisher OpenAlex
  • Type conference-paper
  • Issued 2026

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

· OpenAlex · conference-paper · 2026

Abstract

Objectives: Randomized controlled trials (RCTs) aim to estimate treatment effects in a target population. However, selection based on investigator-defined eligibility criteria (ECs) can lead to limited generalizability and an increased risk of false-negative outcomes [ 1, 2]. Precise optimization of ECs is therefore critical to enhance trial efficiency and statistical power. To address these challenges, we developed an integrated In Silico framework combining mechanistic disease modeling, virtual populations, and mathematical optimization to systematically evaluate and refine ECs, aiming to enhance treatment effect size, statistical power, and overall trial efficiency.

Methods: The framework necessitates: <!-- named anchor --> a QSP disease model with both the natural disease progression and the treatment response [ 3] a representative virtual population capturing clinical variability [ 4] and a detailed trial protocol including treatment arms, randomization, dose administration, and scheduling. Clinical efficacy endpoints can include either continuous, rate-based, or time-to-event outcomes. Optimization algorithms—such as Sobol sequence [ 5] grid search with Monte Carlo refinement—are employed to explore EC combinations.

A composite cost function balances clinical and operational objectives: Cost function = (E × WE) – (SDE × WSD) – (SS × WSS) – (TD × WTD). Where E is mean efficacy, SDE is efficacy standard deviation, SS is sample size, TD is trial duration, and the W terms are user-defined weights. To demonstrate the framework, a synthetic two-arm study was simulated using a large cohort of virtual patients. The underlying physiologically based pharmacokinetic (PBPK) model comprised compartments for blood, lymph, peripheral tissues, and tumor. Eligibility criteria were applied based on selected baseline patient descriptors. Treatment was administered via subcutaneous injection.

Efficacy was assessed as the relative change in tumor burden from baseline, defined as: %ΔTumor = 100 × (Initial – Final) / Initial volume (cm 3). Results: The optimization process identified combinations of eligibility criteria that substantially enhanced trial performance. Compared to a non-optimized design, the optimized scenario resulted in a 35% increase in predicted treatment efficacy and a reduction in required sample size from 548 to 251 patients per arm (–54%). These findings illustrate the efficiency gains achievable through model-based refinement of inclusion criteria.

Conclusions: Integrating QSP modeling with virtual populations and mathematical optimization offers a robust approach to refining clinical trial design. This methodology facilitates the identification of patient subgroups most likely to benefit from treatment, thereby improving trial efficiency and success rates. These In Silico methods are consistent with MIDD practices, which have shown measurable impact on reducing development timelines and clinical trial costs [ 6]. Future work will focus on validating this framework by comparing optimization results.

Open the resolved locator · 10.70534/zdzu1663

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 19:58 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.70534/zdzu1663
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.